Evolutionary Tree Capital Management LLC Sells 161 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Evolutionary Tree Capital Management LLC trimmed its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.8% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 8,935 shares of the company’s stock after selling 161 shares during the quarter. Krystal Biotech accounts for about 1.7% of Evolutionary Tree Capital Management LLC’s holdings, making the stock its 25th biggest holding. Evolutionary Tree Capital Management LLC’s holdings in Krystal Biotech were worth $1,641,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in KRYS. Charles Schwab Investment Management Inc. lifted its stake in Krystal Biotech by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 185,038 shares of the company’s stock worth $22,956,000 after purchasing an additional 5,258 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Krystal Biotech by 5.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 550,806 shares of the company’s stock valued at $68,337,000 after acquiring an additional 30,169 shares during the period. Quest Partners LLC bought a new position in Krystal Biotech during the 4th quarter worth approximately $127,000. Pier 88 Investment Partners LLC purchased a new position in Krystal Biotech in the 4th quarter worth approximately $145,000. Finally, TD Asset Management Inc lifted its position in Krystal Biotech by 82.7% in the fourth quarter. TD Asset Management Inc now owns 40,962 shares of the company’s stock valued at $5,082,000 after purchasing an additional 18,542 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

KRYS stock opened at $184.17 on Friday. Krystal Biotech, Inc. has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The company has a market capitalization of $5.26 billion, a price-to-earnings ratio of 98.49 and a beta of 0.82. The business’s 50 day moving average price is $195.14 and its two-hundred day moving average price is $179.43.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.03. The company had revenue of $70.28 million for the quarter, compared to analysts’ expectations of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm’s revenue for the quarter was up 70283900.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.25) earnings per share. Sell-side analysts forecast that Krystal Biotech, Inc. will post 3.13 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 14.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on KRYS shares. Citigroup restated a “neutral” rating and issued a $204.00 target price (up previously from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Chardan Capital upped their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. HC Wainwright boosted their price target on Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Finally, Stifel Nicolaus upped their price target on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $196.75.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).